Journal: Cancer Cell International

Article Title: Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma

doi: 10.1186/s12935-025-03667-4

Figure Lengend Snippet: Validation of real-world cohort based on the classifier. A The expression levels of CDC7, ASPM, CENPE, KIF23 and DEPDC1B on qRT-PCR results. B By inputting the mRNA levels of the 5 model genes into the classifier, the real-world UCEC cohort was identified as two G2MC subtypes. Representative immunohistochemistry images of CDC7, ASPM, CENPE, KIF23, and DEPDC1B in the two G2MC subtypes, magnification 40x. C K-M survival analysis of two G2MC subtypes based on optimal cutoff value grouping. The ending events are PFS. D The proportion of progression after treatment in the two groups of G2MC subtypes. E Comparing the proportion of patients with pathological grades G1 to G3 in the two G2MC subtypes in the real-world cohort. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Article Snippet: Subsequently, the sections were first incubated with primary antibodies CDC7 (1:200, CUSABIO, China), ASPM (1:200, CUSABIO, China), CENPE (1:500, Sanying, China), KIF23 (1:200, CUSABIO, China), and DEPDC1B (1:200, CUSABIO, China) at 4 °C overnight, and then incubated with multimerized anti-rabbit IgG-HRP secondary antibodies at room temperature for 90 min.

Techniques: Biomarker Discovery, Expressing, Quantitative RT-PCR, Immunohistochemistry